Germany’s lead data protection regulator for Facebook is banning the social network from processing personal data from WhatsApp users because it views the messaging app’s new terms of use as illegal, reported The Economist.
The decision follows emergency proceedings opened by the regulator in the city-state of Hamburg last month after WhatsApp required users to consent to new terms or stop using the service.
“This order seeks to secure the rights and freedoms of the many millions of users who give their consent to the terms of use throughout Germany,” Hamburg’s data protection officer Johannes Caspar said.
“My objective is to prevent disadvantages and damages associated with such a black-box procedure.”
Caspar, who leads domestic oversight of Facebook under Germany’s federal system as its country office is in Hamburg, announced his decision before a May 15 deadline for consenting.
WhatsApp, which is owned by Facebook, stated the action by the Hamburg data protection authority rested on a fundamental misunderstanding of the purpose and effect of its update and therefore had no legitimate basis.
“As the Hamburg DPA’s claims are wrong, the order will not impact the continued roll-out of the update. We remain fully committed to delivering secure and private communications for everyone,” a WhatsApp spokesperson said.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan